Results of base-case analysis
| Cetuximab + FOLFOX-4 | FOLFOX-4 | |
| Costs(US$) | ||
| PFS state | 99 553 | 41 482 |
| PD state | 38 053 | 33 178 |
| Total | 137 606 | 74 659 |
| Incremental costs | – | 62 947 |
| Effectiveness (QALYs) | ||
| PFS state | 0.81 | 0.56 |
| PD state | 1.04 | 0.90 |
| Total | 1.84 | 1.46 |
| Incremental effectiveness | – | 0.383 |
| Incremental cost/effectiveness (US$) | 164 044 |
Results are based on probabilistic analysis and are discounted at 3% per annum rate.
FOLFOX, oxaliplatin, fluorouracil and leucovorin; PD, progressive disease; PFS, progression-free survival; QALY, quality-adjusted life-year.